23.3 : 治疗便秘型肠易激综合征的药物

Irritable bowel syndrome with constipation or IBS-C, is a recurring digestive disorder characterized by abdominal pain and infrequent bowel movements.

Dietary fiber supplements and laxatives soften stool and facilitate bowel movement.

Additionally, linaclotide and lubiprostone are approved for IBS-C treatment.

Linaclotide, a peptide agonist, activates guanylate cyclase-C receptors in the intestinal lining, raising cGMP levels. This stimulates cystic fibrosis transmembrane conductance regulator, or CFTR, resulting in chloride-rich fluid secretions, softening stool and enhancing its passage through the colon, relieving constipation.

Common linaclotide's side effects include diarrhea, gas, abdominal pain, and headaches.

Lubiprostone, a fatty acid derivative, triggers type-2 chloride channels, promoting chloride-rich fluid secretion in the small intestine, aiding in stool softening, and improving bowel motility.

However, it can potentially delay stomach emptying, leading to nausea.

Additional side effects include headache, dyspnea, and allergic reactions.